Universal criteria: Member is at least 18 years of age (unless otherwise specified); member does NOT have any FDA-labeled contraindications to the requested agent (e.g., hypersensitivity to any botulinum toxin product or excipients, hypersensitivity to cow's milk protein, active infection at the proposed injection site); member is not on concurrent treatment with another botulinum toxin;age >=18 when not otherwise specified
From Universal Criteria and Initial Approval
Cervical Dystonia specific: Member has a history of recurrent involuntary contraction of one or more muscles in the neck and upper shoulders AND either sustained head tilt OR abnormal posturing with limited range of motion in the neck
Chunk 6
Spastic conditions: Member has upper or lower limb spasticity (adult) OR pediatric upper/lower limb spasticity in members at least 2 years of age OR hemifacial spasmpediatric >=2 years for pediatric spasticity
Chunk 7
Chronic migraine prophylaxis: Physician-assessed baseline disease severity using an objective tool (e.g., HIT-6, MHD, MIDAS, MPFID); member is utilizing prophylactic intervention modalities; other causes of headache ruled out; diagnosis of chronic migraine defined as >=15 headache days/month for >3 months AND on >=8 days/month for >3 months headaches have migraine features (relief by triptans/ergots OR aura OR migraine characteristics)>=15 days/month; >=8 days/month with migraine features
Chunk 9
Sialorrhea associated with neurological disorders: History of troublesome sialorrhea for at least a 3-month period AND member has Parkinson's disease OR severe developmental delays OR cerebral palsy>=3 months
Chunk 10
Chronic anal fissure: Other causes of disease ruled out; failed non-pharmacologic supportive measures; failed >=1 month trial of conventional pharmacologic therapy (e.g., topical/oral nifedipine, diltiazem, topical nitroglycerin, bethanechol)>=1 month pharmacologic trial
Chunk 11
Neurogenic detrusor overactivity (NDO): Detrusor overactivity associated with a neurologic condition confirmed by urodynamic testing AND failed a 1 month or longer trial of two medications from either the antimuscarinic or beta-adrenergic classesfailed 2 medications, each >=1 month
Chunk 12
Overactive bladder (OAB): Symptoms of urge urinary incontinence, urgency, and frequency AND failed a 1 month or longer trial of two medications from either the antimuscarinic or beta-adrenergic classesfailed 2 medications, each >=1 month
Chunk 13
Severe primary axillary hyperhidrosis: Failed >=1 month trial of a topical agent AND either history of medical complications (e.g., skin infections) OR significant functional impairment/impact on activities of daily living>=1 month topical trial
Chunk 14
Severe palmar hyperhidrosis: Failed >=1 month trial of a topical agent AND failed iontophoresis AND either history of medical complications OR significant impact on activities of daily living>=1 month topical trial
Chunk 15
Ventral hernia (preoperative use): Member has a large ventral hernia with loss of domain or contaminated ventral hernia AND Dysport is used preoperatively in members scheduled to receive abdominal wall reconstruction (AWR)preoperative use for AWR
Chunk 16